Table 5.

Roadmap of AML treatments

ND AML	IC candidate	FLT3 mutation	7 + 3 + midostaurin Clinical trial: 7 + 3 + midostaurin vs 7 + 3 + gilteritinib
		Low, Intermediate risk (CD33 +)	7 + 3 + GO
		Secondary AML	CPX351
		IDH1/2 mutation	7 + 3 or clinical trial
		No targetable Mutation	Clinical trial or 7 + 3 like regimens
		TP53 mutation	Clinical trial or HMA-based regimens
	Not IC candidate	IDH1/IDH2 mutation	Clinical trial HMA + venetoclax LDAC + venetoclax AZA + IDH inhibitor
		FLT3 mutation	Clinical trial HMA + venetoclax LDAC + venetoclax HMA + gilteritinib
		No mutation	Clinical trial HMA + venetoclax LDAC + venetoclax
		TP53 mutation	Clinical trails AZA + magrolimab AZA + APR-246 Off trial: HMA + venetoclax LDAC + venetoclax 5 day or 10 day Decitabine
R/R AML		IC candidate	Re-induction best on the clinical trial
		CD33 +	Clinical trials or GO based regimens,
		IDH1/2 mutation	Ivosidenib/enasidenib alone or HMA combination Venetoclax-based combinations (2 drugs or 3 drugs)
		FLT3 mutation	Gilteritinib alone or combinations with HMA Venetoclax-based combination, (2 drugs or 3 drugs)
		NPM1 mutation or MLL rearrangement	Clinical trials with NPM1/MLL inhibitors Venetoclax-based combination, (2 drugs or 3 drugs)
		TP53 mutation	Clinical trials
		No mutation	Clinical trials Novel first in class agents HMA-base combinations Immunotherapy: MoAbs ADC BiTE/DART Cellular therapies, CAR T, NK cells…